Abbvie Inc.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Stock Performance (90 Days)
Layoff History
Earnings Call Transcripts
View All →AbbVie revised its full-year 2025 adjusted diluted EPS guidance downwards to $10.38 - $10.58, primarily due to a significant $2.68 billion acquired IPR&D and milestones expense incurred in Q3 2025. This strategic investment also impacted Q3 EPS guidance, which is now $1.74 - $1.78. Investors should note the substantial impact of these strategic pipeline investments on near-term earnings.
AbbVie updated its full-year 2025 adjusted diluted EPS guidance to $11.67 - $11.87, and Q2 2025 guidance to $2.84 - $2.88, reflecting an unfavorable $0.42 per share impact from acquired IPR&D and milestones expense. These preliminary Q2 results are subject to finalization, but the company provides clear updated expectations for investors.
AbbVie updated its preliminary Q1 2025 adjusted diluted EPS guidance to $2.34-$2.38 and full-year 2025 guidance to $11.99-$12.19, reflecting a $0.13 per share impact from acquired IPR&D and milestones expense. These estimates are subject to finalization, with the full-year guidance now incorporating the Q1 IPR&D impact.
Recent News
Other Drug Manufacturers - General Companies
View All →
Frequently Asked Questions
Has AbbVie Inc. had layoffs?
How many employees does AbbVie Inc. have?
What industry is AbbVie Inc. in?
Is AbbVie Inc. a publicly traded company?
Where is AbbVie Inc. headquartered?
Disclaimer
Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.
This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.
Found an error? Report it here.